S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:ALXO

ALX Oncology (ALXO) Stock Price, News & Analysis

$11.41
+0.22 (+1.97%)
(As of 03/27/2024 ET)
Today's Range
$10.95
$11.66
50-Day Range
$10.95
$16.79
52-Week Range
$3.94
$17.42
Volume
197,173 shs
Average Volume
361,018 shs
Market Capitalization
$572.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.42

ALX Oncology MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
61.4% Upside
$18.42 Price Target
Short Interest
Healthy
10.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.01mentions of ALX Oncology in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$49,764 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.33) to ($2.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.49 out of 5 stars

Medical Sector

294th out of 939 stocks

Pharmaceutical Preparations Industry

132nd out of 422 stocks

ALXO stock logo

About ALX Oncology Stock (NASDAQ:ALXO)

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

ALXO Stock Price History

ALXO Stock News Headlines

ALX Oncology (NASDAQ:ALXO) Shares Gap Down to $12.51
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Alx Oncology CEO buys $49.7k in company shares
ALXO Apr 2024 7.000 put
ALXO Apr 2024 14.000 put
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
ALXO Apr 2024 19.000 call
ALX Oncology just downgraded at Stifel, here's why
ALX Oncology Holdings Inc.
ALX Oncology: Major Caution Warranted Moving Forward
See More Headlines
Receive ALXO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/27/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALXO
Fax
N/A
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.42
High Stock Price Target
$27.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+61.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-160,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.81 per share

Miscellaneous

Free Float
24,926,000
Market Cap
$572.21 million
Optionable
Optionable
Beta
1.63
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Corey S. Goodman Ph.D. (Age 72)
    Executive Chairman
    Comp: $84k
  • Mr. Jason W. LettmannMr. Jason W. Lettmann (Age 47)
    CEO & Director
    Comp: $60.5k
  • Dr. Jaume Pons Ph.D. (Age 57)
    Founder, President, Director & Chief Scientific Officer
    Comp: $856.29k
  • Mr. Peter S. Garcia M.B.A.Mr. Peter S. Garcia M.B.A. (Age 62)
    Chief Financial Officer
    Comp: $631.11k
  • Dr. Sophia Randolph M.D. (Age 56)
    Ph.D., Chief Medical Officer & Director
    Comp: $637.24k
  • Dr. Michael Chang Ph.D.
    Vice President of Operations
  • Ms. Shelly Pinto (Age 47)
    Senior VP of Finance & Chief Accounting Officer
    Comp: $508.26k
  • Dr. Christopher Byrd J.D.
    Ph.D., General Counsel
  • Dr. Athanasios Tsiatis M.D.
    Senior Vice President of Clinical Development
  • Dr. Lin Yeong-Liang M.D.
    M.S., Senior Vice President of Drug Safety & Pharmacovigilance

ALXO Stock Analysis - Frequently Asked Questions

Should I buy or sell ALX Oncology stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALXO shares.
View ALXO analyst ratings
or view top-rated stocks.

What is ALX Oncology's stock price target for 2024?

7 brokerages have issued 12 month price targets for ALX Oncology's shares. Their ALXO share price targets range from $11.00 to $27.00. On average, they predict the company's share price to reach $18.42 in the next twelve months. This suggests a possible upside of 61.4% from the stock's current price.
View analysts price targets for ALXO
or view top-rated stocks among Wall Street analysts.

How have ALXO shares performed in 2024?

ALX Oncology's stock was trading at $14.89 at the beginning of 2024. Since then, ALXO stock has decreased by 23.4% and is now trading at $11.41.
View the best growth stocks for 2024 here
.

Are investors shorting ALX Oncology?

ALX Oncology saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 2,910,000 shares, a decrease of 16.4% from the February 29th total of 3,480,000 shares. Based on an average trading volume of 377,600 shares, the days-to-cover ratio is presently 7.7 days. Currently, 10.7% of the shares of the stock are sold short.
View ALX Oncology's Short Interest
.

When is ALX Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ALXO earnings forecast
.

How were ALX Oncology's earnings last quarter?

ALX Oncology Holdings Inc. (NASDAQ:ALXO) announced its earnings results on Thursday, March, 7th. The company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by $0.09.

What other stocks do shareholders of ALX Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and

When did ALX Oncology IPO?

ALX Oncology (ALXO) raised $128 million in an initial public offering on Friday, July 17th 2020. The company issued 8,000,000 shares at a price of $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are ALX Oncology's major shareholders?

ALX Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include Vestal Point Capital LP (3.32%), Vanguard Group Inc. (3.02%), Vanguard Group Inc. (3.00%), Point72 Asset Management L.P. (1.83%), Price T Rowe Associates Inc. MD (1.09%) and Price T Rowe Associates Inc. MD (1.09%). Insiders that own company stock include Jason Lettmann, Jaume Pons, Lsv Associates, Llc, Peter S Garcia, Peter S Garcia, Shelly Pinto and Sophia Randolph.
View institutional ownership trends
.

How do I buy shares of ALX Oncology?

Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALXO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners